Technology | July 22, 2014

IBA Receives FDA Approval of New Compact Gantry, Clearing Way for ProteusONE

July 22, 2014 — IBA (Ion Beam Applications SA) announced it has received marketing authorization from the U.S. Food and Drug Administration (FDA) for its compact gantry beam line. IBA anticipates this regulatory approval will intensify the international interest in ProteusONE, IBA’s next-generation proton therapy compact system.

ProteusONE is IBA’s single-room proton therapy system that is smaller, less expensive, faster to install and encompasses the latest in targeted proton therapy technologies, including intensity-modulated proton therapy (IMPT). IBA created the ProteusONE system to allow more patients access to proton therapy globally and has already sold five systems in Shreveport, La.; Nice, France; Taiwan; and two in Japan.

“We are delighted to have received marketing authorization from the FDA for the ProteusONE compact gantry. This is an exciting milestone for our customers in North America, where the cost of healthcare is a major focus. The ProteusONE aligns with the U.S. healthcare trend of providing the highest quality of cancer treatment possible at the best possible price,” said Olivier Legrain, CEO of IBA. “We are confident that ProteusONE will drive greater momentum in the adoption of this next-generation targeted cancer treatment internationally. The approval reaffirms our world-leading position in the delivery of highly targeted, safer cancer treatment solutions. We very much look forward to the first patients at the Willis-Knighton Cancer Center [in Shreveport] benefitting from our compact proton therapy offering later this year.”

Added Lane R. Rosen, M.D., director of radiation oncology at the Willis-Knighton Cancer Centre: “We are very excited to have IMPT become an available option for our patients. The complete clearance of the ProteusONE system, installed at Willis-Knighton, is yet another milestone demonstrating how IBA and WKCC partner for progress.”

ProteusONE is the brand name of a new configuration of the Proteus 235.

For more information:

Related Content

First Hospitals Achieve Inter-System Connectivity Across Accuray Radiation Therapy Platforms
News | Radiation Therapy | January 19, 2018
Accuray Inc. announced recently that the Heidelberg University Hospital in Heidelberg, Germany, and Oscar Lambret...
RayStation Selected for New Carbon Ion Therapy Center in Japan
News | Treatment Planning | January 18, 2018
January 18, 2018 – RayStation has been chosen as the treatment planning system for a new carbon-ion therapy facility
Raysearch Receives First Order for the Raycare Oncology Information System
News | Oncology Information Management Systems (OIMS) | January 18, 2018
January 18, 2018 – Anderson Regional Cancer Center (ARCC) in Meridian, Mississippi, has placed the first order for...
Mevion Receives 510(k) Clearance for Hyperscan Pencil Beam Scanning Proton Therapy
Technology | Proton Therapy | January 04, 2018
Mevion Medical Systems has received U.S. Food and Drug Administration (FDA) 510(k) clearance for the Mevion S250i...
Study Compares Radiosurgery and Whole-Brain Radiation in Lung Cancer Patients With Multiple Brain Metastases
News | Radiation Therapy | January 03, 2018
Although targeted therapies have produced dramatic advances in the ability to control some types of advanced lung...
MEDraysintell Downgrades Proton Therapy Market Projection for 2030
News | Proton Therapy | January 02, 2018
MEDraysintell recently downgraded its projection for proton therapy rooms expected to be operational in 2030 from 1,200...
California US Oncology Network Centers Adopt Xoft Electronic Brachytherapy System for Early-Stage Non-Melanoma Skin Cancer
News | Brachytherapy Systems | January 02, 2018
iCAD Inc. announced that its Xoft Axxent Electronic Brachytherapy (eBx) System is now available at two California-based...
Blue Phantom System Used for Acceptance of First European Varian Halcyon Machine
News | Radiation Therapy | January 02, 2018
IBA (Ion Beam Applications S.A.) announced in November the acceptance and beam model validation of the first Varian...
Study Finds Link Between Breast Cancer Treatments and Cellular Aging Markers
News | Women's Health | January 02, 2018
January 2, 2018 — A new study found women who had received chemotherapy and/or...
ACR Appropriateness Criteria Adds and Revises Topics for December 2017
News | Clinical Decision Support | December 29, 2017
December 29, 2017 — Radiologists can enhance the quality and effectiveness of care with the newest release of the ACR
Overlay Init